Details for New Drug Application (NDA): 202717
✉ Email this page to a colleague
The generic ingredient in MONTELUKAST SODIUM is montelukast sodium. There are thirty-five drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the montelukast sodium profile page.
Summary for 202717
Tradename: | MONTELUKAST SODIUM |
Applicant: | Accord Hlthcare |
Ingredient: | montelukast sodium |
Patents: | 0 |
Pharmacology for NDA: 202717
Mechanism of Action | Leukotriene Receptor Antagonists |
Suppliers and Packaging for NDA: 202717
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
MONTELUKAST SODIUM | montelukast sodium | TABLET;ORAL | 202717 | ANDA | Accord Healthcare Inc. | 16729-119 | 16729-119-10 | 30 TABLET, FILM COATED in 1 BOTTLE (16729-119-10) |
MONTELUKAST SODIUM | montelukast sodium | TABLET;ORAL | 202717 | ANDA | Accord Healthcare Inc. | 16729-119 | 16729-119-15 | 90 TABLET, FILM COATED in 1 BOTTLE (16729-119-15) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 10MG BASE | ||||
Approval Date: | Sep 21, 2012 | TE: | AB | RLD: | No |
Complete Access Available with Subscription